New Antimicrobial Molecules and New Antibiotic Strategies

ABSTRACT

Drug options for treatment of infections are increasingly limited. The pharmaceutical industry has found it difficult to discover new antimicrobial agents, and only two novel classes of antibiotics, the oxazolidinones and the cyclic lipopeptides, have entered the market since the late 1960s. Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin. Agents currently in clinical development include other novel quinolones and ketolides, broad-spectrum cephalosporin derivatives, faropenem, several glycopeptides, and iclaprim. Other molecules are considered to be promising candidates for the future. In addition to the foregoing agents, alternative treatment approaches have also been introduced into clinical practice, which include the administration of the appropriate antimicrobials in a timely manner and the consideration of the pharmacokinetic–pharmacodynamic properties of the agent(s).

KEYWORDS

Antibiotics - new antimicrobials - community-acquired pneumonia - resistance - treatment options

REFERENCES

• 1 Coates A RM, Hu Y. Novel approaches to developing new antibiotics for bacterial infections.  Br J Pharmacol. 2007;  152 1147-1154
• 2 Waldor M K. Disarming pathogens: a new approach for antibiotic development.  N Engl J Med. 2006;  354 296-297
• 3 Mandell L A, Wunderink R G, Anzueto A et al.. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of Community-Acquired Pneumonia.  Clin Infect Dis. 2007;  44 S27-S72
• 4 Felmingham D, Reinert R R, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin.  J Antimicrob Chemother. 2002;  50(Suppl S1) 25-37
• 5 Bosso J A. The antimicrobial armamentarium: evaluating current and future treatment options.  Pharmacotherapy. 2005;  25(10 Pt 2) 55S-62S
• 6 Khardori N. Antibiotics – Past, present, and future.  Med Clin North Am. 2006;  90 1049-1076
• 7 Fagon J, Patrick H, Haas D W et al.. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.  Am J Respir Crit Care Med. 2000;  161 753-762
• 8 Hershberger E, Donabedian S, Konstantinou K, Zervos M J. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.  Clin Infect Dis. 2004;  38 92-98
• 9 Paterson D L. Clinical experience with recently approved antibiotics.  Curr Opin Pharmacol. 2006;  6 486-490
• 10 Owens Jr R C, Ambrose P G. Antimicrobial safety: focus on fluoroquinolones.  Clin Infect Dis. 2005;  41(Suppl 2) S144-S157
• 11 Van Bambeke F, Reinert R R, Appelbaum P C, Tulkens P M, Peetermans W E. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.  Drugs. 2007;  67 2355-2382
• 12 Zhanel G G, Fontaine S, Adam H et al.. A review of new fluoroquinolones: focus on their use in respiratory tract infections.  Treat Respir Med. 2006;  5 437-465
• 13 Kollef M H, Rello J, Cammarata S K, Croos-Dabrera R V, Wunderink R G. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.  Intensive Care Med. 2004;  30 388-394
• 14 Wilcox M H. Efficacy of linezolid versus comparator therapies in gram-positive infections.  J Antimicrob Chemother. 2003;  51(Suppl 2) ii27-ii35
• 15 San Pedro G S, Cammarata S K, Oliphant T H, Todisco T. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.  Scand J Infect Dis. 2002;  34 720-728
• 16 Potoski B A, Adams J, Clarke L et al.. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci.  Clin Infect Dis. 2006;  43 165-171
• 17 Lodise T P, Kinzig-Schippers M, Drusano G L et al.. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.  Antimicrob Agents Chemother. 2008;  52 1945-1951
• 18 Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods G L, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.  J Antimicrob Chemother. 2004;  53(Suppl 2) ii59-ii66
• 19 Alfageme I, Aspa J, Bello S et al.. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía de Tórax.  Arch Bronconeumol. 2005;  41 272-289
• 20 American Thoracic Society . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
• 21 Schmidt-Ioanas M, de Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.  Curr Opin Crit Care. 2005;  11 481-486
• 22 Silverman J A, Mortin L I, Vanpraagh A D, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact.  J Infect Dis. 2005;  191 2149-2152
• 23 Lonks J R, Goldmann D A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.  Clin Infect Dis. 2005;  40 1657-1664
• 24 Wolter N, Smith A M, Low D E, Klugman K P. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2007;  51 1092-1095
• 25 Clay K D, Hanson J S, Pope S D, Rissmiller R W, Purdum III P P, Banks P M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review.  Ann Intern Med. 2006;  144 415-420
• 26 Dore D D, Dibello J R, Lapane K L. Telithromycin use and spontaneous reports of hepatotoxicity.  Drug Saf. 2007;  30 697-703
• 27 Van Bambeke F, Harms J M, Van Laethem Y, Tulkens P M. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.  Expert Opin Pharmacother. 2008;  9 267-283
• 28 Doan T L, Fung H B, Mehta D, Riska P E. Tigecycline: a glycylcycline antimicrobial agent.  Clin Ther. 2006;  28 1079-1106
• 29 Stein G E, Craig W A. Tigecycline: a critical analysis.  Clin Infect Dis. 2006;  43 518-524
• 30 Zhanel G G, Wiebe R, Dilay L et al.. Comparative review of the carbapenems.  Drugs. 2007;  67 1027-1052
• 31 Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.  Crit Care Med. 2008;  36 1089-1096
• 32 Réa-Neto A, Niederman M, Lobo S M et al.. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.  Curr Med Res Opin. 2008;  24 2113-2126
• 33 Keam S J, Perry C M. Prulifloxacin.  Drugs. 2004;  64 2221-2234
• 34 Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis.  Int J Chron Obstruct Pulmon Dis. 2007;  2 27-31
• 35 Jones R N, Sader H S, Stilwell M G, Fritsche T R. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae .  Diagn Microbiol Infect Dis. 2007;  58 1-7
• 36 Hammerschlag M R, Reznik T, Roblin P M, Ramírez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae .  J Antimicrob Chemother. 2003;  51 1025-1028
• 37 Hammerschlag M R, Sharma R. Use of cethromycin, a new ketolide, for the treatment of community-acquired respiratory infections.  Expert Opin Investig Drugs. 2008;  17 387-400
• 38 Anderson S D, Gums J G. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.  Ann Pharmacother. 2008;  42 806-816
• 39 Nicholson S C, Strauss R S, Michiels B, Noel G J. Efficacy of ceftobiprole for the treatment of severely ill patients with hospitalized community-acquired pneumonia [abstract].  Am J Respir Crit Care Med. 2008;  177 A677
• 40 Biek D, Ge Y, Sahm D F. Activity of ceftaroline against common respiratory-associated pathogens from a collection of recent US isolates [abstract].  Am J Respir Crit Care Med. 2008;  177 A677
• 41 Gettig J P, Crank C W, Philbrick A H. Faropenem medoxomil.  Ann Pharmacother. 2008;  42 80-90
• 42 Lentino J R, Narita M, Yu V L. New antimicrobial agents as therapy for resistant gram-positive cocci.  Eur J Clin Microbiol Infect Dis. 2008;  27 3-15
• 43 Attwood R J, LaPlante K L. Telavancin: a novel glycolipopeptide antimicrobial agent.  Am J Health Syst Pharm. 2007;  64 2335-2348
• 44 Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens P M. Glycopeptide antibiotics: from conventional molecules to new derivatives.  Drugs. 2004;  64 913-936
• 45 Kohlhoff S A, Sharma R. Iclaprim.  Expert Opin Investig Drugs. 2007;  16 1441-1448
• 46 Guay D R. Drug forecast: the peptide deformylase inhibitors as antibacterial agents.  Ther Clin Risk Manag. 2007;  3 513-525
• 47 Menéndez R, Torres A, Zalacain R et al.. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome.  Am J Respir Crit Care Med. 2005;  172 757-762
• 48 Menéndez R, Torres A, Rodríguez de Castro F et al.. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.  Clin Infect Dis. 2004;  39 1783-1790
• 49 Meehan T P, Fine M J, Krumholz H M et al.. Quality of care process, and outcomes in elderly patients with pneumonia.  JAMA. 1997;  278 2080-2084
• 50 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.  Arch Intern Med. 2004;  164 637-644
• 51 Berjohn C M, Fishman N O, Joffe M M, Edelstein P H, Metlay J P. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia.  Medicine. 2008;  87 160-166
• 52 Kanwar M, Brar N, Khatib R, Fakih M G. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule.  Chest. 2007;  131 1865-1869
• 53 Waterer G W, Kessler L A, Wunderink R G. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia.  Chest. 2006;  130 11-15
• 54 Schaaf B, Kruse J, Rupp J et al.. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia.  Eur Respir J. 2007;  30 517-524
• 55 Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.  Am J Med. 1999;  107 34S-43S
• 56 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
• 57 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
• 58 Lodise T P, Kwa A, Cosler L, Gupta R, Smith R. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.  Antimicrob Agents Chemother. 2007;  51 3977-3982
• 59 Paul M, Nielsen A D, Gafter-Gvili A et al.. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.  Eur Respir J. 2007;  30 525-531
• 60 Mouton J W, Vinks A A. Continuous infusion of beta-lactams.  Curr Opin Crit Care. 2007;  13 598-606
• 61 File T M. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.  Int J Antimicrob Agents. 2007;  30(Suppl 2) S131-S134
• 62 Swainston Harrison T, Keam S J. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.  Drugs. 2007;  67 773-792
• 63 Li J Z, Winston L G, Moore D H, Bent S. Efficacy of short course antibiotic regimens for community-acquired pneumonia: a meta-analysis.  Am J Med. 2007;  120 783-790
• 64 el Moussaoui R, de Borgie C AJM, van den Broek P et al.. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomised, double blind study.  BMJ. 2006;  332 1355-1360
• 65 Anderson V R, Perry C M. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection.  Drugs. 2008;  68 535-565
• 66 Christ-Crain M, Stolz D, Bingisser R et al.. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia.  Am J Respir Crit Care Med. 2006;  174 84-93
• 67 Oosterheert J J, Bonten M JM, Schneider M ME et al.. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.  BMJ. 2006;  333 1193-1197
• 68 Nathan R V, Rhew D C, Murray C, Bratzler D W, Houck P M, Weingarten S R. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.  Am J Med. 2006;  119 512.e1-512.e7
• 69 Carratalà J, García-Vidal C. What is healthcare-associated pneumonia and how is it managed?.  Curr Opin Infect Dis. 2008;  21 168-173
• 70 Niederman M S. Recent advances in community-acquired pneumonia: inpatient and outpatient.  Chest. 2007;  131 1205-1215
• 71 Rubinstein E, Kollef M H, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus .  Clin Infect Dis. 2008;  46(Suppl 5) S378-S385
• 72 Micek S T, Dunne M, Kollef M H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production.  Chest. 2005;  128 2732-2738